PBS lists medications to reduce severity of COVID-19 19 July 2022 Medications that reduce the severity of COVID-19 are now available on the Pharmaceutical Benefits Scheme (PBS). Oral anti-viral medications, Paxlovid and Lagevrio, can now be prescribed by doctors or authorised nurse practitioners to people living with any type of diabetes who use medication to manage their condition and have another condition. Other conditions include heart or kidney disease or obesity. People living in residential aged care and all people aged 70 and over are also eligible even if they have no risk factors. The medications can be prescribed for: People 50 years of age or older, with two additional risk factors for developing severe COVID-19People 30 years of age or older identifying as Aboriginal or Torres Strait Islander, with two additional risk factors for developing severe diseasePeople 18 years of age or older, who are moderately to severely immunocompromised. The medicines must be started as soon as possible after a diagnosis of COVID-19. If you have developed COVID-19 please speak to your health team about accessing these medicines immediately. It is important to note anti-viral medicines are not intended to be used as substitutes for getting vaccinated against COVID-19. Diabetes Australia continues to recommend people get vaccinated and boosted in line with the latest advice from the Australian Technical Advisory Group on Immunisation.
News 3 July 2026 Daonil to be discontinued in Australia People living with type 2 diabetes who use Daonil are encouraged to speak with their doctor or diabetes healthcare team... Continue Reading
News 30 June 2026 PBS listing of Tresiba Penfill good news for people living with type 1 diabetes Diabetes Australia has welcomed the Australian Government’s decision to list Tresiba Penfill (insulin degludec) on the Pharmaceutical Benefits Scheme (PBS) for people... Continue Reading
Media releases 18 June 2026 Hope for Australians living with cystic fibrosis and diabetes as new research targets breakthrough treatment A leading diabetes and respiratory researcher is investigating whether a breakthrough cystic fibrosis treatment could change the course of a serious form of diabetes affecting Australians living with cystic fibrosis. Continue Reading